Description
While great strides have been made in targeted therapies, an improved understanding of therapy resistance is needed to realize the full potential of precision medicine. Bulk sequencing misses the rare events and underlying genetic diversity across cell populations. To improve patient stratification, therapy selection, and disease monitoring, we need insights into clonal architecture, mutation co-occurrence, and immunophenotype within every single cell. Single-cell DNA and multi-omics analyses enable the simultaneous detection of mutation profiles and immunophenotypes in single cells, so you can stratify patients more precisely, signal resistance as it begins, and predict relapse. Speakers will share the strategies they employ to characterize heterogeneity in cancers at the single-cell level.
Presenters:
- Tractable combinatorial genetics accelerates the functional annotation of cancer genotype-phenotype relationships and the development of clinically relevant disease models
- Speaker: John Lee, M.D., Ph.D., Assistant Professor, Fred Hutchinson Cancer Research Center
- Unleashing the Power of Single-cell Multimodal Analysis to Advance Precision Medicine
- Speaker: Julia Gouffon, Ph.D., Technical Applications Liaison, Mission Bio
